Lonza Group AG's latest marketcap:
As of 06/26/2025, Lonza Group AG's market capitalization has reached $49.79 B. According to our data, Lonza Group AG is the 432th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 49.79 B |
| Revenue (ttm) | 8.19 B |
| Net Income (ttm) | 792.38 M |
| Shares Out | 70.64 M |
| EPS (ttm) | 11.11 |
| Forward PE | 34.44 |
| Ex-Dividend Date | 05/13/2025 |
| Earnings Date | 07/23/2025 |
Lonza Group AG's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/26/2025 | ₣49.79 B | 4.04% | 432 |
| 12/30/2024 | ₣38.7 B | 47.29% | 451 |
| 12/29/2023 | ₣26.27 B | -21.84% | 579 |
| 12/30/2022 | ₣33.62 B | -40.58% | 449 |
| 12/30/2021 | ₣56.57 B | 33.89% | 285 |
| 12/30/2020 | ₣42.26 B | 61.13% | 335 |
| 12/30/2019 | ₣26.22 B | 38.68% | 525 |
| 12/28/2018 | ₣18.91 B | -3.39% | 602 |
| 12/29/2017 | ₣19.57 B | 112.36% | 653 |
| 12/30/2016 | ₣9.22 B | 8.65% | 1111 |
Company Profile
About Lonza Group AG
Lonza Group AG, together with its subsidiaries, supplies a wide range of products and services for pharmaceutical, biotech, and nutrition markets across Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. Founded in 1897 and headquartered in Basel, Switzerland, Lonza operates through four key segments.
Business Segments
- Biologics: Specializes in contract development and manufacturing of biopharmaceuticals, supporting clinical and commercial needs throughout the product lifecycle, including drug substance and drug product manufacturing.
- Small Molecules: Provides integrated development and manufacturing services for small molecule drug substances and intermediates, along with support in design, particle engineering, and drug product packaging.
- Cell & Gene: Develops technologies for cell and gene therapies, offering contract manufacturing, regulatory support, and platforms like the Cocoon system for automated cell therapy production. Also supplies specialty raw materials for injectable drugs and vaccines.
- Capsules & Health Ingredients: Delivers capsules, dosage form solutions, and health ingredients tailored for pharmaceutical and nutraceutical customers.
With a legacy of innovation since 1897, Lonza continues to be a leader in advancing healthcare solutions worldwide.
Frequently Asked Questions
-
What is Lonza Group AG's (SWX-LONN) current market cap?As of 06/26/2025, Lonza Group AG (including the parent company, if applicable) has an estimated market capitalization of $49.79 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Lonza Group AG (SWX-LONN) rank globally by market cap?Lonza Group AG global market capitalization ranking is approximately 432 as of 06/26/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.